PHARM-OLAM INTERNATIONAL ANNOUNCES $25 MILLION OF NEW BUSINESS IN JULY, INCLUDING CLINICAL TRIALS IN LUNG CANCER, RHEUMATOID ARTHRITIS, AND THROMBOEMBOLISM

HOUSTON, TEXAS August 5, 2006. Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announced the award of new contracts with an aggregate value over $25 million. The new contracts involve patient recruitment, site selection, data management, monitoring, and regulatory affairs in a variety of indications including lung cancer, rheumatoid arthritis, and thromboembolism.

The trials will be conducted across North America, Eastern Europe, and India, including several U.S. clinical sites. "We expanded our clinical operations office in Houston, and hired experienced staff throughout North America to meet the increasing demand of sponsors wanting to conduct Canadian and U.S. trials", said Iain Gordon, Director of Global Business Development. "We have also expanded our existing operations in India and now have a larger presence in Bangalore, New Delhi, and Mumbai. Sponsors can handle their Indian trial communications with our corporate offices in the U.S. or U.K.; this has been of particular benefit to our U.S. clients and avoids problems with the differences in time zones."

For further information about Pharm-Olam please contact Iain Gordon at igordon@pharm-olam.com.
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.